New hope for Tough-to-Treat ovarian cancer: experimental drug trial opens
Disease control
Recruiting now
This early-stage study aims to find the safest and most effective dose of an experimental drug called DT2216 when given with standard chemotherapy (paclitaxel) for women with recurrent ovarian cancer that has stopped responding to platinum-based treatments. The trial will enroll …
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC